The epidermal growth factor receptor and its inhibition in cancer therapy - PubMed (original) (raw)
Review
The epidermal growth factor receptor and its inhibition in cancer therapy
J R Woodburn. Pharmacol Ther. 1999 May-Jun.
Abstract
Much effort has been expended in the search for inhibitors of signalling molecules that may prove to be important therapeutically in cancer. The epidermal growth factor receptor (EGFR) family and their associated ligands has been one such area extensively investigated. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Much positive evidence of likely benefit has already been gathered from a multiplicity of laboratory experiments. Clinical trials are now urgently required to further evaluate the advantages of such agents.
Similar articles
- Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
Ghosh S, Liu XP, Zheng Y, Uckun FM. Ghosh S, et al. Curr Cancer Drug Targets. 2001 Aug;1(2):129-40. doi: 10.2174/1568009013334188. Curr Cancer Drug Targets. 2001. PMID: 12188886 Review. - Anti-epidermal growth factor receptor strategies to enhance radiation action.
Lammering G. Lammering G. Curr Med Chem Anticancer Agents. 2003 Sep;3(5):327-33. doi: 10.2174/1568011033482323. Curr Med Chem Anticancer Agents. 2003. PMID: 12871078 Review. - Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27. Pharmacol Res. 2019. PMID: 30500458 Review. - The role of EGFR-directed therapy in the treatment of breast cancer.
Morris C. Morris C. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S51-5; discussion S57-9. doi: 10.1023/a:1020370018668. Breast Cancer Res Treat. 2002. PMID: 12353824 Review.
Cited by
- Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors.
Yang Y, Wang F, Li Y, Chen R, Wang X, Chen J, Lin X, Zhang H, Huang Y, Wang R. Yang Y, et al. Oncol Rep. 2024 Nov;52(5):154. doi: 10.3892/or.2024.8813. Epub 2024 Sep 27. Oncol Rep. 2024. PMID: 39329273 Free PMC article. - Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.
Cheung WY, Carbonell C, Navani V, Sangha RS, Ewara EM, Elia-Pacitti J, Iczkovitz S, Jarada TN, Warkentin MT. Cheung WY, et al. Curr Oncol. 2024 Jul 31;31(8):4382-4396. doi: 10.3390/curroncol31080327. Curr Oncol. 2024. PMID: 39195310 Free PMC article. - A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.
Evans L, Walker R, MacDiarmid J, Brahmbhatt H, Anazodo A, McCowage G, Gifford AJ, Kavallaris M, Trahair T, Ziegler DS. Evans L, et al. Target Oncol. 2024 May;19(3):333-342. doi: 10.1007/s11523-024-01051-2. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546944 Free PMC article. Clinical Trial. - Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study.
Tanaka H, Karita M, Ueda K, Ono T, Kajima M, Manabe Y, Fujimoto K, Yuasa Y, Shiinoki T. Tanaka H, et al. J Pers Med. 2023 Dec 25;14(1):25. doi: 10.3390/jpm14010025. J Pers Med. 2023. PMID: 38248726 Free PMC article. - Busting the Breast Cancer with AstraZeneca's Gefitinib.
Chemmalar S, Intan Shameha AR, Che Abdullah CA, Ab Razak NA, Yusof LM, Ajat M, Chan KW, Abu Bakar Zakaria MZ. Chemmalar S, et al. Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023. Adv Pharmacol Pharm Sci. 2023. PMID: 38090376 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous